<DOC>
	<DOCNO>NCT01535664</DOCNO>
	<brief_summary>The purpose study determine change overall gait well multiple gait balance parameter withdrawal dalfampridine-ER 10mg MS subject receive medication consistently least two week prior screen .</brief_summary>
	<brief_title>An Open Label , Proof Concept Study Evaluate Effects Dalfampridine Withdrawal Gait Balance Parameters Subjects With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>Longitudinal study design</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Diagnosis multiple sclerosis Receiving AmpyraÂ® consistently least 2 week prior screen visit No history seizure except simple febrile seizure Sexually active woman childbearing potential surgically sterile , &lt; two year postmenopause use effective birth control method Subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>